Compare Incyte Corporation (INCY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Materials Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $117.86 (market cap $23.11B), while Materials Select Sector SPDR Fund trades at $50.3. The key difference: Incyte Corporation is trading nearer its 52-week high, Materials Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| INCY | XLB | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $53.62 |
52-Week Low | $67.38 | $42.23 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
XLB trades at $50.03, down 0.99% with a bearish technical bias as moving averages signal selling pressure. The materials ETF faces mixed sentiment with neutral oscillators and key support at $50. Recent news highlights sector rotation potential amid Q2 earnings growth, though Seeking Alpha rates it Hold citing limited upside after recent gains.
Outlook remains cautious with geopolitical and inflation risks weighing on materials demand. Infrastructure trends offer long-term support, but current valuations may already reflect cyclical recovery. Investors should monitor earnings momentum and sector rotation flows for entry opportunities amid bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
